Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
- CAS Registry Number
- 33515-09-2
- Molecular formula
- C55H75N17O13
- Molecular weight
- 1182.31 g/mol
- Drug class
- Gonadotropin-releasing hormone (GnRH) analoguegonadotropin secretagogue
- Mechanism of action
- Binds to and activates pituitary GnRH receptors, stimulating synthesis and release of luteinising hormone (LH) and follicle-stimulating hormone (FSH). The response depends on the dose and pattern of administration.
- Indications / reported uses
- Diagnostic assessment of pituitary gonadotroph function in selected endocrine evaluations.
- Veterinary use to induce LH release and ovulation or manage selected reproductive disorders, according to the authorised species and product.
Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/gonadotropin-releasing-hormone-analog · https://www.ema.europa.eu/en/documents/mrl-report/gonadotrophin-releasing-hormone-gonadorelin-summary-report-committee-veterinary-medicinal-products_en.pdf